Z Squared Inc. (ZSQR): auditor change — Coeptis Therapeutics restates 2022 annual and 2023 quarterly financials; prior reports no longer reliable

Z Squared Inc.

Audit committee determined 2022 audited and 2023 quarterly financials are unreliable due to accounting errors.
Unrecorded liability from October 2022 merger must be booked; remaining balance immaterial and payable in 2024.
Reimbursement commitment under a January 2023 research agreement requires restatement for Q1-Q3 2023.
Company will file restated financial statements as soon as practicable.
Previously disclosed material weaknesses in internal controls; new CFO hired to improve processes.

item 4.02

Key facts

Extracted from this filing and checked against the source text.

Auditor Changes SEC 8-K Item 4.01/4.02 confidence 0.9

Z Squared Inc. reported that prior financial statements should not be relied upon.

Action: non reliance
Auditor: Turner, Stone & Company, L.L.P.

Exact text from the filing

On March 19, 2024, the Audit Committee of Coeptis Therapeutics Holdings, Inc. (“the Company”), after discussions with Management, determined that, due to certain accounting errors described below, the following may no longer be relied upon: (i) the audited consolidated financial statements for the year ended December 31, 2022, included in the Company’s Form 10-K for the year ended December 31, 2022; (ii) the unaudited condensed consolidated financial statements for the periods ended March 31, June 30, and September 30, 2023, included in the Company’s Forms 10-Q for the periods then ended

View on SEC.gov

18 auditor changes filed in the last 30 days. Browse all auditor changes →

Z Squared Inc. filing history →

Source: SEC EDGAR

accession 0001683168-24-001672

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.